Abiraterone and volumetric modulated arc therapy for second recurrence of node-positive prostate cancer – a case report
A case report to analyse the role of abiraterone and volumetric-modulated arc therapy towards prostate cancer.
External Beam Radiotherapy (EBRT) is a noninvasive cancer treatment that uses high-energy beams, such as X-rays, protons, or electrons, to target and destroy cancerous cells within the patient’s body. As one of the most common and widely used methods of radiation therapy, EBRT has emerged as a vital component of modern cancer management, proving effective in treating a variety of malignancies, from localised tumours to metastatic cancer.
The Concept and Mechanism of EBRT
The principle behind EBRT lies in the ability to ionise radiation to damage the DNA within cancerous cells, ultimately inhibiting their ability to divide and proliferate. The high-energy beams used in EBRT are carefully directed at the tumour site, ensuring that the surrounding healthy tissues receive minimal radiation exposure. However, over time, the accumulated radiation dose causes enough damage to the cancer cells that they can no longer repair themselves, resulting in cell death and a reduction in tumour size.
Types of External Beam Radiotherapy
There are several types of EBRT, each utilising different forms of radiation to achieve optimal results:
Treatment Planning and Delivery
Before EBRT can be administered, thorough treatment planning is undertaken to ensure optimal results. This involves imaging studies, such as CT scans or MRIs, to accurately visualise the tumour and its location within the body. With sophisticated software, radiation oncologists design a tailored treatment plan, specifying the radiation dose, beam angles, and treatment schedule.
EBRT treatments are typically delivered over several weeks, with patients receiving daily radiation sessions. The length of treatment depends on factors such as the tumour type, location, and the patient’s overall health.
You are here:
home »
A case report to analyse the role of abiraterone and volumetric-modulated arc therapy towards prostate cancer.